101 related articles for article (PubMed ID: 8369578)
21. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis.
Ohtsuka T
Arch Dermatol Res; 2008 Nov; 300(10):545-50. PubMed ID: 18797895
[TBL] [Abstract][Full Text] [Related]
22. Serum creatinine or glomerular filtration rate for monitoring cyclosporin therapy.
Feutren G; Mason J
Lancet; 1991 Oct; 338(8773):1017. PubMed ID: 1681320
[No Abstract] [Full Text] [Related]
23. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
Salek MS; Finlay AY; Lewis JJ; Sumner MI
Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of plasma fibronectin levels before and after PUVA and cyclosporin A treatments in patients with psoriasis.
Cecchi R; Giomi A; Seghieri G
Dermatology; 1994; 188(3):245-6. PubMed ID: 8186522
[No Abstract] [Full Text] [Related]
25. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A
J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506
[TBL] [Abstract][Full Text] [Related]
26. Short-term treatment with cyclosporin in severe psoriasis: four years of experience.
Garcovich A; Gatti M; Pompili A; Olivetti G; Catamo F
Acta Derm Venereol Suppl (Stockh); 1994; 186():92-3. PubMed ID: 8073852
[No Abstract] [Full Text] [Related]
27. Efficacy of cyclosporin A (CyA) in psoriasis: an overview of dose/response, indications, contraindications and side-effects.
Zachariae H; Steen Olsen T
Clin Nephrol; 1995 Mar; 43(3):154-8. PubMed ID: 7774070
[TBL] [Abstract][Full Text] [Related]
28. Subclinical impairment of distal renal acidification induced by low-dose cyclosporin A therapy.
Quereda C; Soria C; Gallego N; Sabater J; Bermejo M; Pascual J; Ortuño J
Transpl Int; 1992; 5 Suppl 1():S529-31. PubMed ID: 14621867
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.
Altomare G; Ayala F; Bardazzi F; Bellia G; Chimenti S; Colombo D; Flori ML; Girolomoni G; Micali G; Parodi A; Peris K; Vena GA
G Ital Dermatol Venereol; 2016 Aug; 151(4):432-5. PubMed ID: 25786483
[TBL] [Abstract][Full Text] [Related]
30. New method for determining prognosis of patients with psoriasis (E-PAP).
Sugai J; Ozawa A; Kawakubo Y; Iizuka M; Miyahara M; Ohkido M
J Dermatol Sci; 1998 Jan; 16(2):165-9. PubMed ID: 9459130
[TBL] [Abstract][Full Text] [Related]
31. [Renal function during long-term cyclosporin treatment of psoriasis].
Kaoukhov A; Paul C; Lahfa M; Blanchet F; Dubertret L
Ann Dermatol Venereol; 2000 Feb; 127(2):180-3. PubMed ID: 10739977
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients.
Cohen Barak E; Kerner M; Rozenman D; Ziv M
Dermatol Ther; 2015; 28(3):126-30. PubMed ID: 25640261
[TBL] [Abstract][Full Text] [Related]
33. Cyclosporin in childhood psoriasis.
Perrett CM; Ilchyshyn A; Berth-Jones J
J Dermatolog Treat; 2003 Jun; 14(2):113-8. PubMed ID: 12775319
[TBL] [Abstract][Full Text] [Related]
34. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis.
Edwards BD; Bhatnagar D; Mackness MI; Gokal R; Ballardie FW; Chalmers RJ; Durrington PN
QJM; 1995 Feb; 88(2):109-13. PubMed ID: 7704561
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome evaluation following cyclosporine a treatment in moderate to severe psoriasis: a retrospective study.
Colombo D; Flori L; Altomare G; Aste N; Sgarbi S
Int J Immunopathol Pharmacol; 2010; 23(1):363-7. PubMed ID: 20378025
[TBL] [Abstract][Full Text] [Related]
36. Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens.
Zachariae H; Hansen HE; Kragballe K; Olsen S
J Am Acad Dermatol; 1992 Mar; 26(3 Pt 2):415-9. PubMed ID: 1564147
[TBL] [Abstract][Full Text] [Related]
37. Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study.
Colombo D; Cassano N; Altomare G; Giannetti A; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(4):1143-52. PubMed ID: 21244763
[TBL] [Abstract][Full Text] [Related]
38. [Cyclosporine in the treatment of psoriasis].
Bjerke JR
Tidsskr Nor Laegeforen; 1992 Sep; 112(22):2863-5. PubMed ID: 1412327
[TBL] [Abstract][Full Text] [Related]
39. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
[TBL] [Abstract][Full Text] [Related]
40. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin.
Ozdemir M; Yüksel M; Gökbel H; Okudan N; Mevlitoğlu I
J Dermatol; 2012 May; 39(5):443-8. PubMed ID: 22300284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
